Literature DB >> 3899938

In vitro binding of natural killer cells to Cryptococcus neoformans targets.

N Nabavi, J W Murphy.   

Abstract

Nylon wool-nonadherent splenic cells from 7- to 8-week-old CBA mice were further fractionated on discontinuous Percoll gradients. Enrichment of natural killer (NK) cells in Percoll fractions 1 and 2 was confirmed by morphological examination, by immunofluorescent staining, and by assessing the cytolytic activity of each Percoll cell fraction against YAC-1 targets in the 4-h51Cr release assay. Cells isolated from each Percoll fraction were tested for growth-inhibitory activity against Cryptococcus neoformans, a pathogenic yeastlike organism, by using an in vitro 18-h growth inhibition assay. The results showed that NK cell enrichment was concomitant with enrichment of anti-Cryptococcus activity in Percoll fractions 1 and 2. Cells from NK cell-rich fractions formed conjugates with the mycotic targets similar to the conjugates reported in NK cell-tumor systems. In addition, the percentage of effector cell-Cryptococcus conjugates was directly proportional to the level of the C. neoformans growth-inhibitory activity of the effector cells used. Scanning electron microscopy of the effector cell-Cryptococcus conjugates showed direct contact between the effector cells and the cryptococcal targets. An immunolabeling method combined with scanning electron microscopy was used to demonstrate that the effector cells attached to C. neoformans were asialo GM1 positive and, therefore, had NK cell characteristics.

Entities:  

Mesh:

Year:  1985        PMID: 3899938      PMCID: PMC262133          DOI: 10.1128/iai.50.1.50-57.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans.

Authors:  R D Diamond; J E Bennett
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

2.  Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro.

Authors:  R D Diamond; R K Root; J E Bennett
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

3.  Phagocytosis of Cryptococcus neoformans by alveolar macrophages.

Authors:  G S Bulmer; J R Tacker
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

4.  Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection.

Authors:  S C Schimpff; J E Bennett
Journal:  J Allergy Clin Immunol       Date:  1975-06       Impact factor: 10.793

5.  Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing.

Authors:  J C Roder; R Kiessling; P Biberfeld; B Andersson
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

6.  Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.

Authors:  F J Swenson; T R Kozel
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

7.  A glycolipid on the surface of mouse natural killer cells.

Authors:  M Kasai; M Iwamori; Y Nagai; K Okumura; T Tada
Journal:  Eur J Immunol       Date:  1980-03       Impact factor: 5.532

8.  Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis.

Authors:  J W Murphy; N Pahlavan
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

9.  Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  M J Mattes; S O Sharrow; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  21 in total

1.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

3.  Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans.

Authors:  J W Murphy; M R Hidore; N Nabavi
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

5.  Clearance of Giardia muris infection in mice deficient in natural killer cells.

Authors:  M F Heyworth; J E Kung; E C Eriksson
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

6.  Natural killer cells do not play a dominant role in CD4+ subset differentiation in Candida albicans-infected mice.

Authors:  L Romani; A Mencacci; E Cenci; R Spaccapelo; E Schiaffella; L Tonnetti; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans.

Authors:  N Nabavi; J W Murphy
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

8.  Interactions between human natural killer (NK) lymphocytes and yeast cells: human NK cells do not kill Candida albicans, although C. albicans blocks NK lysis of K562 cells.

Authors:  S J Zunino; D Hudig
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

9.  Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans.

Authors:  J W Murphy; M R Hidore; S C Wong
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.

Authors:  M F Miller; T G Mitchell
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.